<DOC>
	<DOCNO>NCT00313183</DOCNO>
	<brief_summary>This study first evaluation Symlin adolescent subject type 1 diabetes mellitus design evaluate blood level ( pharmacokinetics ) , biochemical physiological effect ( pharmacodynamics ) , safety tolerability Symlin subject .</brief_summary>
	<brief_title>A Study Evaluate Symlin Adolescent Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Diagnosed type 1 diabetes mellitus least 1 year prior screen Be stable regimen require multiple daily injection basal mealtime insulin continuous subcutaneous insulin infusion least 2 week prior screen HbA1c 6.0 % 10.0 % , inclusive , screen Body weight &gt; =50 kg screen Currently treat follow medication : *Any oral antihyperglycemic agent ; *Drugs directly affect gastrointestinal motility Has previously treat Symlin/pramlintide ( participate Symlin/pramlintide clinical study ) Has receive investigational drug within 1 month screening</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>pediatric</keyword>
	<keyword>pramlintide</keyword>
	<keyword>Symlin</keyword>
	<keyword>Amylin</keyword>
</DOC>